TLSA: Tiziana Life Sciences, Ltd. Price to Sales

Brandmark of Tiziana Life Sciences Ltd. (TLSA)

The GURU.Markets portal features a chart of the price-to-sales per share ratio, where -20.30 determines this parameter level. Tiziana Life Sciences (TLSA) has established a biotech environment for innovative nasal antibody delivery, protected by exclusive patents. Revenues are based on therapies for Crohn's disease and multiple sclerosis. The humanitarian status of the medicine ensures stable Western partnerships devoid of geopolitical risks.

TLSA - Tiziana Life Sciences Ltd P/S Multiple over the range 07/04/2022 - 08/07/2022

Analytical breakdowns for tizianalifesciences.com (TLSA)

General company analysis:TLSA Tiziana Life Sciences Ltd.
Flagship merchandise of Tiziana Life Sciences

Conservative capital demands a transparent correlation between market value and actual cash flows from sales. This indicator measures the premium the market is willing to pay per unit of revenue, reflecting the balance between current earnings and future growth. For Tiziana Life Sciences (TLSA) and its scalable antibodies, the P/S ratio chart visualizes investor expectations regarding the low cost of mass drug production.

Competitors of Tiziana Life Sciences

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple